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Abstract
Small molecule inhibitors of hepatitis C virus (HCV) are being developed to complement or replace treatments with
pegylated interferons and ribavirin, which have poor response rates and significant side effects. Resistance to these
inhibitors emerges rapidly in the clinic, suggesting that successful therapy will involve combination therapy with multiple
inhibitors of different targets. The entry process of HCV into hepatocytes represents another series of potential targets for
therapeutic intervention, involving viral structural proteins that have not been extensively explored due to experimental
limitations. To discover HCV entry inhibitors, we utilized HCV pseudoparticles (HCVpp) incorporating E1-E2 envelope
proteins from a genotype 1b clinical isolate. Screening of a small molecule library identified a potent HCV-specific triazine
inhibitor, EI-1. A series of HCVpp with E1-E2 sequences from various HCV isolates was used to show activity against all
genotype 1a and 1b HCVpp tested, with median EC50 values of 0.134 and 0.027 mM, respectively. Time-of-addition
experiments demonstrated a block in HCVpp entry, downstream of initial attachment to the cell surface, and prior to or
concomitant with bafilomycin inhibition of endosomal acidification. EI-1 was equally active against cell-culture adapted HCV
(HCVcc), blocking both cell-free entry and cell-to-cell transmission of virus. HCVcc with high-level resistance to EI-1 was
selected by sequential passage in the presence of inhibitor, and resistance was shown to be conferred by changes to
residue 719 in the carboxy-terminal transmembrane anchor region of E2, implicating this envelope protein in EI-1
susceptibility. Combinations of EI-1 with interferon, or inhibitors of NS3 or NS5A, resulted in additive to synergistic activity.
These results suggest that inhibitors of HCV entry could be added to replication inhibitors and interferons already in
development.
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Introduction
Hepatitis C virus (HCV), a member of the Flaviviridae family
of positive-strand RNA viruses, chronically infects approxi-
mately 170 million people worldwide [1,2]. Over time,
ongoing virus replication within the liver often leads to severe
clinical manifestations such as fibrosis, cirrhosis, and hepato-
cellular carcinoma [3,4]. Consequently, HCV-induced disease
is the leading indication for liver transplantation [5]. Medical
treatment for HCV is limited by the lack of a vaccine or
approved therapies that specifically target the virus. Currently,
patients undergo treatment with a combination of parenterally
administered pegylated interferon-alpha (IFN-a)a n do r a l
ribavirin [6]. Genotype 1 HCV has proven to be the most
difficult to treat and elimination of the virus (sustained
virologic response) is achieved for only approximately 50%
of patients [7,8]. This poor treatment response, combined with
often severe side effects induced by therapy, highlight a need
for improved antiviral drugs with better efficacy and safety
profiles.
Studies with isolated HCV replication enzymes and replicon
cell-based systems have been exploited to identify several inhibitors
of HCV replication that are currently in clinical development [9].
While these have demonstrated potent reduction of circulating
virus in early clinical trials, preexisting or rapidly-emerging
resistance is a characteristic of the highly mutable HCV genome
[9,10]. As with HIV treatment paradigms, these results dictate that
combination therapy, targeting multiple stages or functions of the
HCV infection cycle, will be required to treat HCV. Therefore, we
sought to search for inhibitors that could complement those
currently in development.
HCV encodes two envelope glycoproteins, E1 and E2, which
together mediate binding and entry of the virus into primary
hepatocytes and hepatocyte cell lines. The sequence of events
leading to virus internalization has not been completely defined,
but recent evidence implicates several cell surface molecules in
the process. The initial attachment (adsorption) of the virus is
likely facilitated by a low affinity interaction of E2 with heparan
sulfate proteoglycans (HSPGs) on the cell surface [11,12,13].
Subsequently, higher affinity interactions with several host cell
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entry. These include the low-density lipoprotein receptor
(LDL-R) [14,15,16], the tetraspanin CD81 [17,18,19,20,21,22],
scavenger receptor class B type I (SR-BI) [18,19,20,23,24,25,26],
and tight junction proteins claudin (CLDN)-1, 6, or 9, and
occludin [27,28,29,30]. In vitro, non-permissive human, mouse,
and hamster cell lines become permissive to infection with HCV
pseudoparticles (HCVpp) if engineered for ectopic expression of
S R - B I ,C D 8 1 ,C L D N 1 ,a n do c c l u d in suggesting these are the
core HCV receptors required for entry of the virus into
hepatocytes [29]. The LDL-R is postulated to function
primarily in the context of serum HCV particles, and may
facilitate the attachment or uptake of virions which are
complexed with very low density lipoproteins in vivo [31]. There
is some evidence to suggest that HCV interacts with CD81 and
SR-BI earlier in the entry pathway, followed by CLDN1 and
occludin at tight junctions, although the exact order of bind-
i n ga n dt h er o l eo fe a c hr e c e p t o rr e m a i nt ob ed e t e r m i n e d
[18,23,27].
Following receptor binding, virions are internalized via clathrin-
mediated endocytosis [32,33,34,35]. By analogy to the phylogen-
eticlly related flaviviruses [36,37,38], the reduced pH of the
endosome is thought to mediate a conformational change in the
HCV virion that facilitates fusion of the viral and endosome
membranes, depositing the nucleocapsid into the cytoplasm.
Indeed, agents that prevent the acidification of the endosome
block HCV entry if added within 3 hr after infection [39].
Structural features characteristic of class II viral fusion glycopro-
teins of flaviviruses and alphaviruses [40,41] have been identified
within HCV E1 and E2, and it remains to be determined if one or
both of these proteins mediate the fusion process [42,43,44,45,46].
HCVpp, which consist of retroviral or lentiviral cores
surrounded by an envelope containing HCV E1 and E2, have
proven to be a valuable surrogate system by which to study the
viral and cellular determinants of the viral entry pathway [47,48].
The early steps of infection by infectious cell culture HCV
(HCVcc), including receptor binding, internalization, and pH-
dependent endosomal fusion, are mimicked by HCVpp. In
addition, pseudoparticles can be engineered to express reporter
proteins, affording a convenient system to quantify E1E2-
mediated entry in the absence of other HCV-encoded functions.
The HCVpp system is easily amenable to genetic manipulation of
E1 and E2, allowing the characterization of envelope protein
genotype variation and identification of functionally important
regions through mutagenesis.
The molecular targets for current HCV direct-acting antiviral
agents in drug development are focused on the non-structural
proteins required for replication such as the NS3 protease, NS5A,
and the NS5B RNA-dependent RNA polymerase. The viral entry
pathway encompasses several additional potential points for
intervention, and therapies targeting entry would provide a
differentiated mechanism that could be a component of future
drug combination regimes [49]. Here, we characterize a small
molecule entry inhibitor identified through a high-throughput
HCVpp screening effort. The inhibitor is most potent against
genotype 1 HCV and functions at a post-HSPG binding step,
prior to or concomitant with fusion. Using chimeric HCVcc
expressing genotype 1a, 1b, or 2a envelope proteins, we
demonstrate comparable potency and the ability to block cell-to-
cell spread. HCVcc resistant to this molecule was isolated and
amino acid changes were mapped to a residue in the transmem-
brane domain (TMD) of E2, distinct from regions identified in
receptor-binding functions. Combination of the entry inhibitor
with IFN-a or other HCV-specific antivirals resulted in additive to
synergistic activity.
Materials and Methods
Cells and culture conditions
293T cells (ATCC, Manassas, VA), Huh-7 cells (a gift from Ralf
Bartenschlager), and Huh-H1 cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS) (HyClone,
Logan, UT), 2 mM L-glutamine, 1mM sodium pyruvate, 10%
nonessential amino acids, 10 mM HEPES, 100 units/ml penicillin,
and 100 units/ml streptomycin. Huh-7.5 cells (Apath, Brooklyn,
NY) were maintained in DMEM containing 10% FBS, 10%
nonessentialaminoacids,100 units/mlpenicillin,and 100 units/ml
streptomycin. Madin-Darby canine kidney (MDCK) cells (ATCC)
were maintained in Minimum Essential Medium (MEM) (Invitro-
gen, Carlsbad, CA) containing 5% FBS and 0.1% sodium
bicarbonate. Madin-Darby bovine kidney (MDBK) cells (ATCC)
were maintained in DMEM supplemented with 10% Ultra-Low
IgG FBS (Invitrogen), 2 mM L-glutamine, 100 units/ml penicillin,
and 100 units/ml streptomycin. MT2 cells were obtained from the
NIH Research and Reference Reagent Program and maintained in
RPMI 1640 supplemented with 10% FBS, 10 mM HEPES, 2 mM
L-glutamine, 100 units/ml penicillin, and 100 units/ml strepto-
mycin.
Generation of cells expressing high levels of CD81
CD81 cDNA was isolated from Huh-7 cells by reverse
transcriptase PCR (RT-PCR) and cloned under the transcriptional
control of the CMV IE promoter in pcDNA3.1(-) (Invitrogen) to
create p131-C1. Huh7B cells were transfected with p131-C1 using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
protocol and subjected to selection with 1 mg/ml G418. Limiting
dilution and flow cytometry using anti-CD81 monoclonal
antibody (BD Biosciences, San Jose, CA) were used to segregate
the cells expressing the highest levels of CD81. A cell clone,
designated here as Huh-H1, was expanded and maintained in
media containing 0.5 mg/ml G418.
Author Summary
Approximately 170 million people worldwide are chroni-
cally infected with hepatitis C virus (HCV), which is a
leading cause of chronic liver disease. Current treatments
are not optimal; however, several molecules that inhibit
HCV replication are in development. However, resistance
to individual antivirals is likely to develop, requiring
therapy consisting of a combination of drugs targeting
different stages of the viral life cycle. The entry of HCV into
hepatocytes is a multistep process, involving at least four
cellular receptors, leading to virion endocytosis and fusion
of the viral and cellular membranes. Unlike the HCV
replication process, these steps have not been thoroughly
exploited as targets for antiviral intervention. Therefore,
we screened a small molecule library for inhibitors of HCV
entry and identified a compound, EI-1, that potently
blocked genotype 1a and 1b HCV infection. Importantly,
EI-1 also prevented direct cell-to-cell spread of HCV, a
potentially significant route of transmission in infected
livers. In addition, our studies suggest that EI-1 suscepti-
bility is mediated by the viral E2 envelope glycoprotein, as
resistance in E2 can overcome inhibition. The antiviral
activity of EI-1 is potentiated by combinations with other
HCV inhibitors, demonstrating the value of entry inhibitors
in potential combination antiviral regimens.
HCV Entry Inhibitor
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HCV RNA was isolated from infected human sera, obtained
following informed consent, using the QiaAmp Viral RNA
Extraction kit (Qiagen, Valencia, CA) according to the manufac-
turer’s instructions. HCV RNA was reverse transcribed using
Thermoscript (Invitrogen) and genotype-specific primers designed
using publically available sequences. Subgenomic amplicons
harboring complete core-p7 regions were amplified using geno-
type-specific forward primers within the HCV 59 UTR and reverse
primers within NS2 or NS3. Sequences encoding the last 21
amino acids of core (E1 signal sequence) through the end of E2
were amplified using patient-specific primers and cloned into
pcDNA3.1(+) (Invitrogen) for HCVpp production. HCVpp pseu-
dotyped with envelope proteins from genotype 1b isolate 432-4
(GenBank accession number HM049503) were used for the com-
pound library screening, as well as other experiments presented
here. Prototypical laboratory HCVpp envelopes were derived from
genotype 1a H77C (GenBank accession number AF009606),
genotype 1b Con1 (GenBank accession number AJ238799),
genotype 2a JHF1 (GenBank accession number AB047639), or
genotype 2a J6 (GenBank accession number AF177036) and cloned
into expression vector pcDNA3.1(+).
Preparation of viral pseudoparticles
Murine leukemia virus (MLV)-based pseudoparticles containing
HCV E1E2 or vesicular stomatitis virus (VSV) glycoprotein G
envelope proteins were produced by a modification of published
procedures [47,48]. Briefly, 3.5610
7 293T cells were transfected
with 17.5 mg of pVPack-GP (Stratagene, La Jolla, CA) expressing
the murine leukemia virus capsid and polymerase proteins,
17.5 mg of pFB-luc2 (a derivative of pFB-luc (Stratagene) in which
the firefly luciferase gene was replaced with a human codon
optimized firefly luciferase from pGL4.10 (Promega, Madison WI))
encoding an MLV genome expressing luciferase reporter gene,
and 4.4 mg of either pVSV-G (Clontech, Mountain View, CA)
expressing the VSV envelope glycoprotein G or one of the HCV
E1E2-expressing plasmids (above). Transfections were performed
for 6 hrs using Lipofectamine 2000 as described by the
manufacturer (Invitrogen), at which time the medium was
removed and replaced with DMEM/10% FBS. Media containing
HCV pseudoparticles (HCVpp) or VSV pseudoparticles (VSVpp)
was collected 3 days following transfection, clarified by passage
through a 0.45 mm filter (Millipore, Bedford, MA), and stored at
270uC as a viral stock.
HCVpp infection assays
For compound library screening, infections were performed in
384-well plates by mixing HCVpp or VSVpp with 1610
4 Huh-H1
cells/well in the presence or absence of test inhibitors, followed by
incubation at 37uC. Luciferase activity, reflecting the degree of
entry of the pseudoparticles into host cells, was measured 2 days
after infection using the Steady-Glo Reagent (Promega). Test
compounds were serially diluted 3-fold in dimethyl sulfoxide
(DMSO) to give a final concentration range in the assay of
50.0 mM to 0.04 pM. Maximum activity (100% of control) and
background were derived from control wells containing DMSO
alone or from uninfected wells, respectively. The individual signals
in each of the compound test wells were then divided by the
averaged control values (wells lacking inhibitor), after background
subtraction, and multiplied by 100% to determine percent activity.
The corresponding % inhibition values were then calculated by
subtracting this value from 100. Assays were performed in
triplicate and average EC50 values (reflecting the concentration
at which 50% inhibition of virus replication was achieved) were
calculated using XLfit for Excel (ID Business Solutions, Burling-
ton, MA). The specificity of the compounds for inhibiting HCV
was determined by evaluating inhibition of VSVpp infection in
parallel.
Preparation of cell culture adapted HCV (HCVcc)
HCVcc utilized consisted of chimeric viruses containing
structural genes from genotype 1a, 1b, or 2a and nonstructural
regions from genotype 2a JFH-1. The full length JFH1 genome
was chemically synthesized. The genotype 1a chimeric JFH1 virus
containing the H77C structural region (HCV-1a/2a) was
constructed as described [50]. The genotype 1b chimeric JFH1
virus, containing the core to the NS2 C3 junction from the
genotype 1b isolate 432-4 (HCV-1b/2a), was constructed as
described [51]. The genotype 2a chimeric JHF1 virus containing
the J6CF structural region (HCV-2a/2a) was constructed as
described [51]. Chimeric reporter viruses contained an in-frame
Renilla luciferase gene (HCVcc-1a/2a-Rluc, HCVcc-1b/2a-Rluc,
and HCVcc-2a/2a-Rluc) inserted in-between the NS5A and
NS5B coding sequences such that the NS3 protease cleavage
sequences were reconstituted on either side of luciferase (Burt
Rose, unpublished). In vitro RNA was prepared from these cloned
sequences using the MEGAscript kit (Ambion, Austin, TX) and
transfected by electroporation into Huh-7.5 cells as described [52].
Media containing virus was collected, clarified by low speed
centrifugation, and stored at 270uC. HCVcc titers were
determined by infection of Huh-7.5 cells with serial dilutions of
virus, followed by indirect immunofluorescence for HCV core
protein as described below, and expressed as focus forming units
(ffu)/ml. Virus preparations required several passages for adapta-
tion required to generate high titer stocks.
HCVcc infection assays
Infections utilizing HCVcc chimeras expressing the Renilla
luciferase protein were quantified by infecting Huh-7.5 cells (with
or without inhibitors), incubating at 37uC for 3 days, and
measuring luciferase activity using the EnduRen substrate
(Promega) as described by the manufacturer. Infections utilizing
HCVcc without a reporter were quantified by indirect immuno-
fluorescence. HCVcc was added to Huh-7.5 cells (with or without
inhibitors) in special-optics, collagen-coated 96-well plates (BD
Biosciences) and incubated at 37uC for 2–4 days. Cells were then
washed twice with PBS and fixed with 4% paraformaldehyde in
PBS (Sigma) for 30 min at room temperature. Following 2 washes
in PBS, cells were permeabilized with 0.25% Triton X-100 (Pierce,
Rockford, IL) in PBS for 10 min and blocked with 2% bovine
serum albumen (Sigma) in PBS for 30 min. Samples were
incubated for 2 hr with 3 mg/ml anti-HCV Core monoclonal
antibody (ABR-Affinity Bioreagents, Golden, CO), washed 4 times
with PBS, and incubated with a 1/500 dilution of Alexa Fluor 488-
labeled donkey anti-mouse secondary antibody (Invitrogen) for
1 hr. Samples were washed three times with PBS and 0.5 mg/ml of
Hoechst 33258 (Sigma) was added to the final wash to visualize
nuclei. Infected cell foci were visualized using a Nikon Eclipse
TE300 inverted epi-fluorescence microscope. EC50 determinations
were performed as described above.
Antiviral selectivity assays
EI-1 was serial diluted in DMSO as above and added to cells
and virus during infection. Influenza virus cell protection assays
were performed essentially as described [53] by infecting MDCK
cells with 0.005 plaque forming units (pfu)/cell of influenza virus
strain A/WS/33 (ATCC). Infected cells were incubated at 37uC
for 3 days and virus-induced cytopathicity was measured using the
HCV Entry Inhibitor
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were performed essentially as described [54] by infecting MDBK
cells with 0.1 pfu/cell of BVDV strain NADL. Infected cells were
incubated at 37uC for 3 days and virus-induced cytopathicity was
measured using the Cell Titer-Glo reagent (Promega). HIV assays
were performed as described [55] by infecting MT2 cells with
0.05 pfu/cell of the NL4-3 strain of HIV (NIH Research and
Reference Reagent Program) containing the Renilla luciferase gene
(NL-Rluc) in the Nef locus. Infected cells were incubated at 37uC
for 5 days and virus replication was measured by reverse
transcriptase assay using a scintillation proximity assay as
described [55].
Inhibitor time-of-addition assays
Huh-H1 cells were seeded at 5610
3 cells/well in 96-well plates.
The following day the plates were chilled to 4uC and the media
was removed and replaced with HCVpp inoculum in a volume of
50 ml. Plates were incubated at 4uC for 1.5 hr on a rocking
platform. The inoculum was removed and unbound virus was
removed by 2 washes with 4uC media. Fresh media was added and
the plates were shifted to a 37uC incubator. 200 mg/ml porcine
intestinal heparin (Sigma), 10 nM bafilomycin A1 (Sigma),
2 mg/ml anti-CD81 monoclonal antibody (BD Biosciences), or
0.125 mM EI-1 were added at specific time points during infection.
At 3 days post infection, firefly luciferase activity was quantified
using the Steady-Glo Reagent (Promega) according to the
manufacturer’s instructions. Experiments were done in triplicate
and the mean % inhibition was calculated relative to control
infections lacking inhibitor.
HCVcc release assay
Huh-7.5 cells were plated in 24-well plates at 6.5610
4 cells/well
and infected with HCVcc-1b/2a at 2 ffu/cell in the presence of
EI-1 (40 or 200 nm), 8 nM NS5A inhibitor BMS-790052 [56], or
DMSO control. Cells were incubated at 37uC for 5 hrs, after
which the inoculum was removed and the monolayers washed 36
with phosphate buffered saline (PBS). Fresh media was added
containing inhibitors or DMSO as above and the cells incubated
at 37uC. Wells in which inhibitors were present continually for the
duration of the infection measured the effect on entry, whereas
wells that received inhibitors at 5 hrs post infection measured the
effect on post-entry events. Media was removed at 2 days post
infection and clarified by centrifugation at 1,0006g for 5 min. To
titer the infectious HCVcc, media was serially diluted and virus
quantified by indirect immunofluorescence as described above. To
measure total viral particles released into the media, HCV RNA
was isolated from 0.05 ml of culture supernatants using the
MagMax-96 Viral RNA Isolation Kit (Ambion, Austin, TX)
according to the manufacturer’s protocol. Purified HCV RNA was
analyzed by quantitative RT-PCR using the AgPath-ID One-Step
RT-PCR Kit (Ambion) according to the manufacturer’s protocol
using HCV specific forward primer (59-CGG GAG AGC CAT
AGT GG-39), reverse primer (59-AGT ACC ACA AGG CCT
TTC G-39) and probe (59-FAM-CTG CGG AAC CGG TGA
GTA CAC-BHQ-39) (Biosearch Technologies, Novato, CA).
Samples were run on an Applied Biosystems 7900HT instrument
using the 40-cycle RT-PCR protocol and the data analyzed using
the SDS 2.2.2 software (Applied Biosystems, Foster City, CA). All
results are the mean of triplicate assays.
HCVcc cell-to-cell transmission assay
An assay incorporating a semisolid medium was used to access
cell-to-cell spread as described [57]. HCVcc-1a/c2a was added to
1.6610
4 Huh-7.5 cells at 0.001 ffu/cell incubated at 37uC. At
12 hr post infection, the inoculum was removed and replaced with
DMEM/2% FBS/1% Seaplaque low melting temperature
agarose (Lonza, Rockland, ME) containing EI-1 (0.5 mM) or an
equivalent volume of DMSO control. Cells were incubated at
37uC for 2, 3 or 4 days at which time the agarose was removed
and the infected cells were detected using indirect immunofluo-
rescence for the HCV core protein as described above. The mean
number of infected cells/ffu was determined from $100 foci for
each data point.
HCVcc resistance selection
HCVcc-1a/2a or HCV-1b/2a was used to infect Huh-7.5 cells
in media containing EI-1. Either infected cells or cell-free virus
from media was serially passaged and selective pressure was
progressively increased in sequential passages by raising the
concentration of the inhibitor present. HCVcc replication in the
presence of EI-1 was monitored by determining the spread of virus
infection, using immunofluorescence, at each passage. Generally,
virus stocks were prepared when HCVcc was $50-fold resistant
relative to wild-type parental virus. The HCV genome was
amplified by RT-PCR, cloned and amino acid changes that arose
during inhibitor selection were identified by analysis of the DNA
sequence compared to the parent and control passages in the
absence of inhibitor.
Inhibitor combination experiments
EI-1 was tested individually or in combination with NS5A
inhibitor BMS-790052 [56], NS33 inhibitor BMS-605339 [58], or
recombinant IFN-a-2b (Myoderm Medical Supply, Norristown,
PA). Antiviral assays were performed with HCVcc-1a/2a-Rluc,
and quantified as described above. Concentration-response curves
were fit to the normalized responses from each inhibitor. The
combination indices (CI) and Lowe’s synergy were determined and
analyzed as described [59]. In practice, additivity is indicated if the
CI=1.0, synergy if the CI,1.0, and antagonism if the CI.1.0.
To take into account the inherent variability involved with
cultured cells, the calculated 95% confidence intervals for all of the
combination indices were presented. The final results were derived
from 8 independent experiments for each combination.
Results
Identification of HCVpp inhibitors
An HCV pseudoparticle (HCVpp) infection system, utilizing a
firefly luciferase reporter, was developed for high-throughput
screening (HTS) of a small molecule library of .1 million
compounds for inhibitors of HCV entry. In order to facilitate the
screen, assay performance was improved by modifying the
properties of the parental host cell line and the pseudovirus. First,
we created a Huh-7B-derived cell population (Huh-H1) that
overexpresses the CD81 receptor in order to improve HCVpp
entry [60], resulting in an enhancement to HCVpp infection of
approximately 3 fold relative to the parental Huh-7B cells (data
not shown). Second, HCVpp used for the HTS contained
envelope proteins E1 and E2 that were derived from genotype
1b clinical isolate 432-4 (HCVpp-1b). Infection with these
pseudoparticles resulted in an approximate 3-fold increase in
luciferase activity relative to HCVpp containing the prototypical
1b Con1 envelope proteins (data not shown). Third, the
pseudoviruses were engineered to express a human codon
optimized luciferase reporter that improved the sensitivity of the
assay by increasing activity approximately 100-fold compared to
wild-type firefly luciferase (data not shown).
HCV Entry Inhibitor
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Huh-H1 cells for 2 days, at which time viral entry was quantified
by luciferase activity. Compounds found to inhibit HCVpp-1b
infection were then counterscreened against pseudoparticles
containing the genotype 1a H77C envelope proteins (HCVpp-
1a) and pseudoparticles containing the VSV glycoprotein G
envelope protein (VSVpp) in order to identify HCVpp-selective
inhibitors. From this process, counterscreens against other viruses,
and structure-activity relationship (SAR) testing using other
compounds from the collection, we identified a chemical series
consisting of several structurally related compounds defined by a
common triazine core. An example of one such compound, EI-1
(Fig. 1A), inhibited HCVpp-1b and VSVpp with EC50 values of
0.01660.001 and 3362.1 mM respectively, giving a VSVpp/
HCVpp selectivity index of .2,000 (Fig. 1B). Other studies
showed that pseudovirus with MLV envelope proteins was also not
inhibited (data not shown). Because HCVpp and VSVpp differed
only in their viral envelope proteins, and both pseudoparticles
enter cells via the clathrin-mediated endocytosis pathway, the
results suggested that the inhibitors targeted the HCV E1E2
proteins and not common cellular factors utilized for entry.
Synthetic chemistry efforts were used to further explore the
SAR of the triazine series using EI-1 [N
2-(4-nitrophenyl)-N
4-
pentyl-6-(2,2,2-trifluoroethoxy)-1,3,5-triazine-2,4-diamine] as a
starting point. Our initial synthetic strategy focused on identifying
an equipotent replacement for the pharmaceutically undesirable
nitro group. A library of compounds was synthesized to explore
the effect of substitutions at the 49 (para) and 39 (meta) positions of
the aniline ring (Fig 1A), and these compounds were assessed for
activity against HCVpp-1a and HCVpp-1b (Table 1). Removing
the nitro group from EI-2 afforded a 3- to 6-fold decrease in
potency in the HCVpp 1a and 1b assays, respectively. Surpris-
ingly, the electron-donating p- and m-methoxy analogs (EI-3 and
EI-9) were equipotent with the corresponding nitro group-
containing analogs, while the p- and m-methyl analogs (EI-4 and
EI-10) afforded HCVpp EC50 values within 4-fold of the
corresponding nitro analogs. In contrast, introduction of the
electron-withdrawing p-CF3 group (EI-5) resulted in a 15- to 45-
fold decrease in 1a/1b potency in comparison with EI-1. This
activity discrepancy did not extend to the m-CF3 analog (EI-11),
which afforded equipotent genotype 1a/1b activity in comparison
with the m-nitro analog (EI-8). As illustrated with EI-6 and EI-7,
the introduction of para substituents which more closely mimicked
the shape and polarity of the nitro group afforded sub-100 nM
EC50 values in both the 1a and 1b HCVpp assays, but the HCVpp
1a activity was significantly diminished for the meta-substituted
analogs EI-12 and EI-13. All analogs contained in Table 1
provided greater than 10-fold VSV selectivity, indicating that the
activity of the compounds did not arise from cytotoxicity.
EI-1 is selective for genotype 1 HCVpp
In order to investigate the activity of EI-1 against various HCV
genotypes, we established HCVpp containing E1 and E2 proteins
from different genotypic backgrounds. Serum samples from
patients infected with HCV genotypes 1–5 were used as a source
for cloning the E1E2 coding sequences by RT-PCR. Individual
clones were then tested for the ability to support pseudovirus
infectivity. From this process, a collection of HCVpp containing
functional envelope proteins from each of 40 separate patient
samples was obtained. The panel consists of 16 genotype 1a
isolates, 15 genotype 1b isolates, 2 isolates each of genotypes 2a,
2b, 3a, and 4a, and 1 genotype 5a isolate. The potency of EI-1 was
Figure 1. Compound structure and activity in the HCVpp assay.
(A) Structure of EI-1. (B) Dose dependent inhibition of HCVpp-1b
infectivity by EI-1. Huh-H1 cells were infected with HCVpp-1b or VSVpp
in the presence of various concentrations of EI-1, incubated at 37uC, and
luciferase activity was measured 3 days post infection. Data are
presented as percent inhibition relative to control infections lacking
compound. Results are expressed as mean and standard deviation from
triplicate assays. EI-1 EC50 values are 0.01660.001 and 3362.1mM for
HCVpp and VSVpp, respectively.
doi:10.1371/journal.ppat.1001086.g001
Table 1. Structure-activity-relationship of the EI-1
chemotype.
Sample Id R
b EC50 (mM)
a
HCVpp-1a HCVpp-1b VSVpp
EI-1 p-NO2 0.211 0.016 33
EI-2 H 0.721 0.115 36
EI-3 p-OCH3 0.185 0.024 33
EI-4 p-CH3 0.789 0.085 38
EI-5 p-CF3 3.219 0.933 .50
EI-6 p-CO2tBu 0.047 0.009 .50
EI-7 p-CONH2 0.042 0.007 .50
EI-8 m-NO2 0.165 0.016 11
EI-9 m-OCH3 0.095 0.054 24
EI-10 m-CH3 0.179 0.072 28
EI-11 m-CF3 0.095 0.060 11
EI-12 m-CO2tBu 1.022 0.016 14
aMean of $3 independent experiments.
bR, aniline ring substituent (Fig 1A).
doi:10.1371/journal.ppat.1001086.t001
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VSVpp, EI-1 potently and selectively inhibited all 31 genotype 1
isolates with median 1a and 1b EC50 values of 0.134 and
0.027 mM, respectively (1a range 0.007–1.2 mM, 1b range 0.005–
0.2 mM). By contrast, EI-1 inhibition of HCVpp genotypes 2–5
was minimal, with EC50s of 7.1 to .36 mM (equivalent to VSVpp
activity, thus likely through nonselective cell cytotoxicity). Greater
potency towards genotype 1 HCV was a characteristic of other
related analogs tested (data not shown), providing further support
to the hypothesis that the target of the compounds was likely to be
a viral factor and not a general HCV entry cellular factor.
EI-1 inhibits infection by cell culture-adapted HCV
While HCVpp are thought to enter cells in a manner analogous
to authentic HCV, it was important to validate the antiviral
activity of EI-1 using the fully replicating cell culture-adapted
HCV (HCVcc). HCVcc luciferase reporter virus chimeras
HCVcc-1a/2a-Rluc, HCVcc-1b/2a-Rluc, or HCVcc-2a/2a-Rluc
expressing either genotype 1a (H77C), 1b (432-4), or 2a (J6)
structural proteins, respectively, in the JFH1 background were
utilized for these experiments. Huh-7.5 cells were infected in the
presence of EI-1 and productive infection was determined by
measuring luciferase activity at 3 days post infection. Infection by
the genotype 1a/2a and 1b/2a chimeras was prevented, with
EC50 values of 0.024 and 0.012 mM, respectively (Table 2). EI-1
was not active against genotype 2a/2a chimeric virus, consistent
with the results obtained with the genotype 2a HCVpp (Fig. 2).
Although EI-1 displayed similar potency against HCVcc and
HCVpp expressing the genotype 1b 432–4 envelope proteins
(Table 1 and Table 2), EI-1 was 8.8-fold more potent against
HCVcc expressing the genotype 1a H77C envelope proteins as
compared to the corresponding HCVpp. This may be related to
the observation that the 1a/2a chimeric virus infection spreads
more efficiently relative to the 1b/2a chimeric virus in culture
(unpublished observations). The resulting additional rounds of
replication can increase the apparent potency of the entry
inhibitors in the HCVcc system vs.the single-cycle HCVpp assay.
EI-1 selectivity for HCVcc was assessed by determining the
activity against a panel of viruses that enter cells by fusion with the
plasma membrane (HIV) or, like HCV, undergo pH-dependent
fusion with the endosomal membrane (BVDV and Influenza). In
addition, compound-induced cytotoxicity in each cell line used for
the infection assays was measured. No significant inhibition by EI-
1 was observed against these viruses at concentrations up to the
cytotoxic levels (.50 mM), which was markedly removed from the
concentrations that were active against HCV (Table 2). These
results support the antiviral specificity of the EI-1 HCV inhibitor.
EI-1 inhibits an early post-attachment step of entry
Although EI-1 blocked HCVcc infection, no inhibition of
genotype 1a or 1b HCV replicons was observed (data not shown).
To confirm that EI-1 acted at the entry stage of infection, we
characterized the kinetics of compound activity using time-of-
addition assays. Synchronous infection was initiated by adding
HCVpp-1b to Huh-H1 cells at 4uC for 1.5 hr to allow attachment
to the cell surface, presumably through HSPGs [11,12,13].
Unbound virus was removed and the temperature was shifted to
37uC to allow entry to proceed. EI-1 (0.125 mM) was then added
at various time intervals up to 4 hrs. To define the endpoint of the
entry process, bafilomycin A1, an inhibitor of endosomal
acidification that prevents the final fusion step between the virus
envelope and the endosomal membrane, was tested in a parallel
assay. As previously reported [39], sensitivity to bafilomycin was
lost at times $3 hrs after the 37uC temperature shift, indicating
that HCVpp entry and fusion were completed within this time
frame (Fig. 3A). The kinetics of EI-1 activity demonstrated that
inhibition was likewise exerted within 3 hours of infection,
confirming a point of action during HCVpp entry. Similar results
were obtained with the HCVcc virus (data not shown).
We next examined whether EI-1 blocks the initial attachment
step to HSPGs, or a downstream event in the HCV entry process.
EI-1 was added together with HCVpp to cells during the 4uC
attachment step only, and then removed prior to shifting to 37uC.
Alternatively, EI-1 was added only following the temperature shift
to measure the effect on the post-attachment events. Control
inhibitors included the heparan sulfate homolog heparin, a
monoclonal antibody against the CD81 receptor, and bafilomycin
A1. As previously reported, heparin was only effective at
Figure 2. HCV genotype coverage of EI-1. Huh-H1 cells were mixed with HCVpp or VSVpp in the presence of various concentrations of EI-1.
Infected cells were incubated at 37uC and luciferase activity was determined 3 days post infection. The average EC50 ($2 experiments) of each of the
40 isolates representing HCV genotypes 1–5 (triangles), as well as VSVpp (square), is shown.
doi:10.1371/journal.ppat.1001086.g002
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while the CD81 monoclonal antibody and bafilomycin were only
effective during the post-attachment stage (Fig 3B). EI-1 had little
effect on the attachment of HCVpp to HSPGs, but exhibited
.90% inhibition when added after the 37uC infection phase.
Taken together, the data demonstrate that EI-1 blocks an event in
HCV entry that lies temporally downstream of attachment to
HSPGs, either prior to or during fusion.
EI-1 blocks cell-to-cell spread of HCV
Following infection of Huh-7.5 cells with cell-free HCVcc,
transmission of the virus to adjacent cells results in focal areas of
spreading infection (foci). Cell-to-cell spread of HCV differs
from infection with cell-free virus in that it is refractory to
neutralization by HCV E2 monoclonal antibodies and occurs in
a CD81-independent manner [57,61], thus representing an
alternative mode of transmission that may be important in vivo.
We therefore conducted experiments to determine if EI-1 could
block cell-to-cell spread in culture. Huh-7.5 cells were infected
with the HCVcc-1a/2a chimera at a ratio of 0.001 infectious
units per cell. At 12 hr post infection, the inoculum was
removed and replaced with a semisolid medium/agarose
overlay that has been shown to prevent the cell-free diffusion
of virus but not cell-to-cell transmission [57]. Discrete foci
formed in the presence of the agarose overlay lacking EI-1
(Fig 4A), although they were somewhat smaller in size compared
to those observed using a liquid medium (data not shown),
consistent with previous observations [57]. Foci size increased
over time, from an average of 2 infected cells at day 2 to an
average of 40 infected cells at day 4 (Fig 4B). However, in the
presence of EI-1, cell-to-cell transmission was abrogated
(Fig 4A), with foci containing only an average of 6 infected
cells/focus at 4 days post infection (Fig 4B). This foci size
represents division of the initially-infected cell only (data not
shown). In addition, the total number of foci did not increase
between days 2 and 4, indicating that the agarose overlay was
effective in preventing the formation of satellite foci that can
result from the cell-free dissemination of virus from the primary
sites of infection (Fig 4C). Overall, these results demonstrate that
EI-1 is effective at preventing HCVcc infection by the cell-to-
cell transmission pathway.
If EI-1 mediates inhibition of cell-free virus and cell-to-cell
spread via interaction with E1 and/or E2, compound binding to
the envelope protein(s) during viral replication or assembly could
result in a decreased virus production or infectivity, consequently
decreasing the luciferase signal and foci size. To address the
potential effects of the entry inhibitor on the post-entry events of
the HCV life cycle, EI-1 was added to the culture either during
HCVcc infection, or 5 hours later. At two days post-infection, total
virions (HCV RNA copies) and infectious virus (HCV ffu) released
into the cell media were quantified. As expected, if EI-1 was
present during entry, there was a dose-dependent reduction in
subsequent progeny virus release (Fig 5). However, addition of EI-
1 post entry did not affect the levels of virion particles or infectious
virus produced. In contrast, an NS5A inhibitor BMS-790052,
which targets HCV replication [56], prevented virus release when
added 5 hours post infection. These results demonstrate that the
EI-1 antiviral activity is confined to the pre-replication (entry)
stage of infection.
Figure 3. Kinetics of inhibition by HCV entry inhibitors. (A) Time course of inhibition. HCVpp (1b) was added to Huh-H1 cells at 4uC and
incubated for 1.5 hr. Unadsorbed virus was removed by 2 washes with cold media, fresh media was added, and the cells were shifted to 37uC to allow
synchronous infection to proceed. At the indicated time points, the media was removed and replaced with media containing 0.125 mM EI-1 (triangles
and solid line) or 10 nM bafilomycin A1 (squares and dashed line) and incubated at 37u for 3 days. Inhibition was calculated as a % relative to control
infections containing inhibitor throughout the experiment (100%) and those lacking inhibitor (0%). The 21.5 hr time point, in which inhibitor was
present throughout the infection, represents maximum inhibition. Mean values and standard deviations were calculated from triplicate wells and the
results presented are from a representative of multiple experiments. (B) Attachment and post-attachment efficacy of inhibitors. Infections were
performed as described in (A). Heparin (200 mg/ml), anti-CD81 monoclonal antibody (2 mg/ml), EI-1 (0.125mM), or bafilomycin A1 (10 nM) were
present in the media either continuously, during the 4uC incubation only (attachment), or during the 37uC incubation phase only (post-attachment).
Inhibition was calculated as % relative to control infections lacking inhibitor. Results are expressed as mean and standard deviation from 3
independent experiments.
doi:10.1371/journal.ppat.1001086.g003
Table 2. Activity of EI-1 in infectious virus assays.
Virus Cell Line EC50 (mM)
a CC50 (mM)
a
HCVcc-1a/2a-Rluc Huh-7.5 0.024 .50
HCVcc-1b/2a-Rluc Huh-7.5 0.012 .50
HCVcc-2a/2a-Rluc Huh-7.5 50.1 .50
BVDV MBCK .50 .50
Influenza virus MDCK .50 .50
HIV MT2 23.4 .50
aMean of $4 independent experiments.
doi:10.1371/journal.ppat.1001086.t002
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To investigate whether E1 and/or E2 is the molecular target of
EI-1, experiments were performed to determine if HCVcc
resistance to the compound could be achieved by selective
pressure in cell culture. HCVcc-1a/2a or HCVcc-1b/2a chimeras
were propagated for several passages in the presence of increasing
concentrations of EI-1. Virus was monitored for decreased
susceptibility (increased EC50) to the compound at intervals during
the selection procedure and by increased spreading of the virus
through immunofluorescence detection of HCV core protein.
When the HCVcc population had become $50-fold resistant
relative to the untreated controls, and virus spreading to
uninfected cells was abundant, the virus population was isolated
and the genome amplified by RT-PCR. Changes in the DNA and
amino acid sequence of the entire HCV polyprotein were then
determined. Two independent selection experiments were con-
ducted with independent stocks of HCVcc-1a/2a. Both EI-1
resistant virus isolates contained an amino acid substitution at
residue 719 of the E2 protein (based on the H77C polyprotein
numbering) in which valine changed to either phenylalanine or
glycine (Table 3). E2:V719G also emerged in a third selection
experiment using the HCVcc-1b/2a chimera, together with an
E1:V227V/A mixture. In two of the virus populations, additional
amino acid changes were also identified in non-structural proteins
NS4B and NS5A.
To determine the role each of the amino acid changes in the
EI-1 resistance phenotype, substitutions were introduced sepa-
rately into wild-type HCVcc or HCVpp by site-directed
Figure 4. Effect of EI-1 on HCV cell-to-cell spread. (A) Huh-7.5 cells were infected with 0.001 ffu/cell HCVcc-1a/2a at 37uC. At 12 hrs post
infection, the inoculum was removed and replaced with medium +1% agarose overlay containing EI-1 (0.5 mM) or DMSO and the cultures were
incubated at 37uC for 2, 3 or 4 days. Infected cells were labeled by indirect immunofluorescence using an anti-HCV core monoclonal antibody (green)
and nuclei were stained with Hoechst 3325 (red). Images were captured using a Nikon Eclipse TE300 inverted epi-fluorescence microscope. (B) The
mean number and standard deviation of infected cells/focus was determined from visual counting of infected cells in $100 foci for each time point.
(C) The mean number and standard deviation of foci/well was determined at 2 and 4 days post infection.
doi:10.1371/journal.ppat.1001086.g004
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seemed unlikely to contribute to resistance of an HCV entry
inhibitor. To test this hypothesis, the single E2:V719G
substitution was created in the HCVcc-1a/2a chimera and the
resistance level of this clone was compared to the EI-1-selected
virus containing the E2:V719G+NS4B:T1936A+NS5A:I2345T
(Table 3). Similar resistance levels were observed (86 vs. 91-fold/
WT), suggesting the E2 mutation alone confirmed the HCVcc
resistance phenotype (Table 4). Next, to confirm that the
HCVcc resistance to EI-1 is mediated at the level of viral entry,
each of the E1 and E2 substitutions that emerged during
selection were tested in the HCVpp background. The E2:V719F
and G substitutions recapitulated resistance to EI-1 in both
genotype 1a and 1b HCVpp (Table 4). However, in contrast to
the HCVcc results, the E2:V719G substitution in the genotype
1a background rendered the HCVpp completely resistant to
EI-1 (.5,000 fold/WT). The only substitution found in the E1
envelope protein during selection with EI-1, V227A, conferred a
small (,2-fold) increase in resistance when present alone, and
did not contribute significant additional resistance in combina-
tion with E2:V719G.
Residue 719 is located within the proposed carboxy-terminal
TMD of E2 near the interface with the ectodomain (Fig 6).
Examination of E2 sequences containing this region in public
database repositories revealed that 719V is the predominate amino
acid, present in 85% of sequences. The resistance changes
identified here, V719F and V719G, were not found. Other
naturally occurring polymorphisms at E2:719 are isoleucine,
leucine, and alanine. E2:719I is found in 14% of sequences
(typically genotypes 1b, 5, and 6). This variant is represented in
genotype 1a, 1b, and 5a isolates in our HCVpp genotype panel
(Fig. 6), yet the genotype 1 HCVpp were fully susceptible to EI-1
(1b EC50 range 0.016–0.052 mM, 1a EC50 0.041 mM). V:719L or
A was found in only 1% of publicly available sequences. These
variants were constructed by site-directed mutagenesis and found
to impart moderate (V719L, 17-fold WT) to high (V719A, 317-
fold WT) levels of resistance to EI-1 (Table 4). Overall, the results
implicate changes to E2 residue 719 in EI-1 resistance in genotype
Figure 5. Effect of EI-1 on virus replication, assembly and release. Huh-7.5 cells were infected with HCVcc-1b/2a at 2 ffu/cell in the presence
of EI-1 (40 or 200 nM), 8 nM NS5A inhibitor BMS-790052, or DMSO control. Cells were incubated at 37uC for 5 hrs, after which the inoculum was
removed and the monolayers washed 3 times with phosphate buffered saline (PBS). Fresh media was added containing inhibitors or DMSO as above
and the cells incubated at 37uC for 2 days. Wells in which inhibitors were present continually for the duration of the infection measured the effect on
entry, whereas wells that received inhibitors at 5 hrs post infection measured the effect on post-entry events. Infectious HCVcc released into the
media was quantified by indirect immunofluorescence using an anti-HCV core monoclonal antibody (ffu/ml). Total viral particles released into the
media were measured by HCV-specific quantitative RT-PCR (copies/ml). Results are expressed as the mean and standard deviation of triplicate assays.
doi:10.1371/journal.ppat.1001086.g005
Table 3. E1 and E2 amino acid changes that emerged during selection with EI-1.
Exp # Virus Amino Acid Substitutions Resistance (fold/WT)
a
E1 E2 Other
1 HCVcc-1a/2a - V719F - 52
2 HCVcc-1a/2a - V719G NS4B:T1936A, NS5A:I2345T 86
3 HCVcc-1b/2a V227V/A V719G NS5A:L2249L/M 63
aFold increase in EC50 compared to wild-type virus. Values represent the mean of $3 experiments.
doi:10.1371/journal.ppat.1001086.t003
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which are intrinsically resistant to EI-1, contain E2:719V or I,
suggesting susceptibility is likely modulated by other residues or
regions as well (Fig. 6).
Entry and replication inhibitor are efficacious when
combined
Due to the high rate of preexisting or emerging viral resistance,
effective treatment of HCV-infected patients will likely require a
combination of inhibitors targeting distinct viral or host functions.
Therefore, we performed experiments using the HCVcc-1a/2a-
Rluc chimera to characterize the antiviral effects of the EI-1 entry
inhibitor in combination with HCV replication inhibitors
targeting NS5A (BMS-790052) [56] or NS3 (BMS-605339)
[58], or IFN-a. Each inhibitor was tested alone or in combination
with entry inhibitor EI-1. The data from 8 replicate experiments
were analyzed for departure of the results from additivity at the
EC50 level for each combination using the Loewe model as
described by Chou [59]. By this method, a combination index
(CI) equal to 1 indicates additivity, and a CI,1o r.1 indicates
synergy or antagonism, respectively. Combinations of EI-1 with
the NS5A inhibitor or IFN-a resulted in CIs of 0.95–0.96,
reflective of additivity (Table 5). The NS3 protease inhibitor
combined with EI-1 gave a CI of 0.82, indicative of a moderate
degree of synergy. Similar results were also obtained for all
combinations at the EC90 level (data not shown). The absence of
antagonism likely results from the mechanistically distinct targets
of the entry and replication inhibitors, and indicates that entry
inhibitors could provide a valuable component of combination
therapy.
Discussion
HCV entry represents an attractive target for drug discovery
from a mechanistic view, with opportunities to prevent multiple
virus-receptor interactions and to interfere with virus-cell mem-
brane fusion [49]. Each of these steps, although not completely
defined, is likely mediated by the HCV E1 and/or E2 envelope
glycoproteins. In vitro, proof-of-concept for inhibiting the HCV
entry process has been demonstrated using cyanovirin-N that
targets the N-linked glycans of the viral envelope proteins and
prevents E2-CD81 interaction [62], neutralizing antibodies
directed against the HCV E1 and E2 proteins [63,64,65,66,
67,68], antibodies against cellular receptors CD81 [17,18,19,
20,21,22] and SR-BI [17,18,19,20,21,22], and agents that block
endosomal acidification [39,48]. In vivo studies using human liver-
u-PA-SCID mice have also demonstrated prophylactic efficacy of
anti-CD81 antibodies [69]. In the present study, we used the
HCVpp system in order to isolate the entry pathway from other
HCV replication functions, and undertook a screening campaign
that led to discovery of a class of small molecule HCV-specific
inhibitors, exemplified by EI-1. Inhibition of entry was confirmed
by using time-of-addition experiments to demonstrate that EI-1
activity is confined to the first 3 hours of infection, with inhibition
occurring post-attachment and closely linked to the inhibition
kinetics of the endosomal acidification inhibitor bafilomycin.
EI-1 does not inhibit entry of VSVpp, which also undergoes
receptor-mediated endocytosis and pH-dependent endosomal
fusion, thus making cellular factors required for internalization
unlikely targets of this compound. Furthermore, although EI-1
i n h i b i t e da l l3 1g e n o t y p e1 aa n d1 bi s o l a t e si no u rH C V p p
panel, activity towards isolates with envelope genotypes 2–5 was
greatly diminished. This result also argues against a cellular
p r o t e i na st h et a r g e tf o rE I - 1a ss u c ha ni n h i b i t o rs h o u l dd i s p l a y
similar activity across genotypes. Lastly, genotype 1 HCVcc
resistance to EI-1 is conferred by a V719F/G change in the
C-terminal TMD region of HCV E2, supporting the concept
that EI-1 blocks HCV entry by inhibiting the function of the
HCV envelope glycoproteins. It is tempting to speculate that EI-
1 binds to E2 in part through an interaction with the valine or
isoleucine residue 719. Alternatively, E2:V719 may represent an
allosteric site, whereby changes induce a conformational
alteration of E2 and/or E1 that prevent EI-1 binding. However,
the E2 protein of genotypes 2–5 in our HCVpp panel also
contains valine or leucine, yet these isolates are not susceptible
to EI-1suggesting the determinant(s) for the intrinsic resistance
of non-genotype 1 HCV may lay elsewhere. Indeed, further
HCVcc resistance selection experiments suggest that changes to
residues within E1 can also modulate susceptibility to other
members of the EI-1 chemotype (data not shown). Ultimately,
conclusive evidence for the target of EI-1 awaits biophysical
experiments designed to demonstrate a direct compound-
protein interaction.
It was critical to determine whether the EI-1 entry inhibitor
prevented infection by HCVcc as well as HCVpp. While
experimental findings obtained with the HCVpp model have
generally extended to those with the HCVcc system, this is not
always the case. For example, while a small molecule targeting SR-
BI [70] potently inhibits HCVcc infection, it does so at a markedly
reduced potency in the HCVpp system (unpublished observations).
More importantly, however, it was unclear if small molecule
inhibitors discovered through the HCVpp system could prove to
inhibit HCVcc infection, especially since much of the HCVcc
infection occurs through a cell-to-cell transmission route that is
shielded from neutralizing antibodies [57] and bypasses the
requirement for the CD81 receptor [61]. Since it is assumed that
cell-to-cell infection is an important feature of viral pathogenesis,
inhibitors that operated through both prevention of cell-free virus
infection and cell-to-cell spread of virus would logically be needed
for therapy. Our results demonstrate that EI-1 is potent at
blocking genotype 1 HCVpp and HCVcc entry, as well as direct
cell-to-cell spread of HCVcc. However, because circulating HCV
in patients is highly associated with lipoprotein particles
[31,52,71,72,73,74], it will be important to determine the efficacy
of EI-1 and similar HCV entry inhibitors in cell culture systems
using serum-derived HCV or in human liver chimeric mouse
model systems [69].
Table 4. EI-1 resistance levels of site-directed changes
engineered into HCVcc or HCVpp.
Virus Amino Acid Substitutions Resistance (fold/WT)a
E1 E2
HCVcc-1a/2a - V719G 91
HCVpp-1a - V719F 53.5
HCVpp-1a - V719G .5,000
HCVpp-1b V227A V719G 89.8
HCVpp-1b V227A - 1.9
HCVpp-1b - V719G 77.0
HCVpp-1a - V719L 17
HCVpp-1a - V719A 317
aFold increase in EC50 compared to wild-type virus. Values represent the mean
of $3 experiments.
doi:10.1371/journal.ppat.1001086.t004
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be solved. However, high-resolution structural models for the
related flavivirus class II envelope glycoproteins of dengue virus,
tick-borne encephalitis virus, and West Nile virus have been
reported in both the pre- and post-fusion states [36,75,76,77]. It is
unclear how the HCV E1 and E2 proteins perform the functions of
the homologous proteins in other flaviviruses. However, structural
features characteristic of class II viral fusion proteins, such as a
membrane proximal heptad repeat and a putative hydrophobic
fusion peptide have been identified within both E1 and E2
[42,43,46,78]. In addition, other laboratories have used mutational
analysis to ascribe E1-E2 heterodimerization, entry, and membrane
fusion functions to residues inthe E2stem and TMD [79,80]. These
results have lead to the hypothesis that flavivirus glycoproteins form
intermolecular hairpin motifs projecting hydrophobic fusion
peptides that facilitate the final fusion of viral envelopes with
Figure 6. Schematic diagram of the HCV E2 protein and sequences of the region encompassing the EI-1 resistance residue.
Previously defined regions of the protein are indicated by the shaded boxes. Numbers correspond to the HCV polyprotein amino acid positions in E2.
HVR1, hypervariable region 1. HVR2, hypervariable region 2. pFP1 and pFP2, putative fusion peptide regions. igVR, intergenotypic variability region.
HR, heptad repeat. TMD, transmembrane domain. The asterisk indicates the position of residue 719 that is involved in EI-1 resistance. The protein
sequence alignment from amino acids 709–729 for each of the HCVpp genotype isolates from Figure 2 is shown. The shaded residues are part of the
TMD.
doi:10.1371/journal.ppat.1001086.g006
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elucidating the mechanism of inhibition may contribute to
understanding the functional roles of the HCV envelope proteins.
A dengue virus entry inhibitor, the detergent n-octyl-b-D-
glucoside (b-OG) was found to bind to a hydrophobic pocket
formed ina postulated hinge region betweendomains I and II inthe
viral envelope E protein [36]. Several other inhibitors of dengue
virus entry were found based on an exercise of modeling candidate
compounds into this pocket [82,83]. Modeling of domains I, II and
III of the dengue E protein with HCV E1 and E2 proteins suggested
that theb-OGsite between domains IIandIII localizedtotheHCV
E2protein andnot toE1.Whileb-OGdidnot inhibit HCVentryin
ourhands (data not shown),itis unclearwhat portion of HCV E1 or
E2 may be analogous to the hinge region. In contrast to the b-OG
binding site, which is within the soluble fragment of dengue virus E
protein, HCV resistance to the EI-1 compound described here
maps to the second amino acid of the putative TMD region of
genotype 1 E2.Perhaps multiplebindingsiteswithintheHCV entry
proteins exist, accessible during the numerous conformational states
that may operate during receptor binding and fusion. Consistent
withthisconcept isthe findingthatduringourowndiscoveryefforts,
several HCV entry inhibitors with diverse structural characteristics
and resistance mapping were identified (data not shown). Down-
streamimplications ofthesefindingsarethepossibilitythat multiple,
diverse inhibitors of HCV entry could contribute to combination
therapy for HCV.
Similarities between the HCV entry inhibitors described here
and diverse compounds inhibiting the entry of arenaviruses into
cells are intriguing. Both pseudotype [84] and infectious virus
screening [85] identified broadly active arenavirus entry inhibitors.
Isolation and mapping of resistant viruses, as well as chimeras
between sensitive and resistant strains, mapped the target of
activity to the GP2 subunit of the G envelope protein complex,
specifically the interface between the C-terminal stem and TMD
domains [84,85]. These results are strikingly similar to those
described in the current work in that resistance to EI-1 occurs in
the same region of the genotype 1 HCV E2 envelope glycoprotein
Mechanistic studies showed that these arenavirus inhibitors
prevented low-pH-induced fusion by blocking reorganization
between the GP2 stem with N-terminal domains of the G protein
complex [86]. By analogy, perhaps the HCV entry inhibitors
described here prevent pH-induced reorganization of the HCV
E1E2 complex that mediates fusion [81].
The activity surrounding the search for antivirals targeting
HCV is considerable. Each antiviral therapy is accompanied by a
unique set of challenges for its development. Although HCV entry
inhibitors could be a valuable component of therapy, their
development will provide differences from those of replication
inhibitor compounds, currently in clinical development. Preclinical
development of entry inhibitors require infection assay formats,
with pseudotyped or full-length HCV, such as those described
here. While capable experimental systems have been developed,
these are not as robust as many virus systems such as HIV,
influenza or herpesviruses. HCV replication inhibitor assays, on
the other hand, require assays with the more facile stable,
transformed, replicon cell line. The inherent genetic variation in
viral envelope proteins also presents a unique target for entry
inhibitors. We have addressed these issues with various assay
systems and an HCVpp genotype panel assembled from patient
isolates, which demonstrated the genotype 1 specificity of EI-1.
Furthermore, as noted above, it has been reported that the viral
envelope lipoprotein content differs between cell culture HCV and
virus isolated from patients. Additionally, cellular receptors and
entry processes may vary from the transformed cells used here and
primary hepatocytes. For these reasons, it will be important to
evaluate the efficacy of small molecule HCV entry inhibitors in
primary cells, using patient-derived virus, and potentially in in vivo
model systems. Finally, current HCV inhibitor clinical studies
have been limited in duration to prevent the development of
resistance. The efficacy of these replication inhibitors, however,
can quickly be assessed through circulating levels of HCV RNA
produced by chronically-infected cells. Since entry inhibitors will
prevent new infections of uninfected cells, they will have no
immediate impact on the levels of circulating virus in the blood.
Thus, more protracted clinical studies may be required.
Several small molecule inhibitors have been advanced to the
clinic, and some have progressed after an initial high attrition rate
[87]. Unfortunately, both the high replication and error rates of the
viral polymerase leads to exceeding diversity of viral sequences, thus
resulting in preexisting and rapidly emerging resistance [9,10,88].
Despite potent efficacy, it is now well understood that combinations
of inhibitors, including both small molecules targeting the virus and
interferon regimens acting through host targets, will be required for
optimal treatment [9,88]. By analogy to HIV, safe, potent inhibitors
of multiple viral targets will be needed to prevent resistance from
emerging or for optimal management of patients with resistance.
We have shown the EI-1 entry inhibitor functions additively or
synergistically with other HCV replication inhibitors and IFN-a in
the HCVcc cell culture assay system. Entry inhibitors, such as those
describedhere, byvirtue oftheir distinct,relatively new targets, may
provide a valuable component in the eventual optimal therapy for
HCV infection.
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